// App-Quantinova.ai

[FRI0168] : SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY IN HEALTHY VOLUNTEERS

Researchers

Presenter

  • C. Schwabe

Principal Investigators

  • F. Wagner

  • I. Filler

  • J. Habeck

  • R. Thiedmann

  • S. Padula

  • J. Steffgen

  • M. Albulescu

  • P. Rose

  • B. Emerson

  • T. Doan

  • B. Rosenstock

  • D. Joseph

  • J. Hilbert

  • C. Scholch

Medical Centers

  • Translational Medicine, Boehringer-Ingelheim, Biberach, Germany

  • Clinical, Boehringer-Ingelheim, Sydney, Australia

  • Clinical Development, Boehringer-Ingelheim, Ingelheim, Germany

  • Auckland Clinical Studies Limited, Auckland, New Zealand

  • Translational Medicine, Boehringer-Ingelheim, Ridgefield, United States

Locations

  • United States

  • Germany

  • New Zealand

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Venous thrombosis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • BI 655064

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved